GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET

Company Participants

Christian Dinneen-Long - Company Counsel

Harout Semerjian - President and Chief Executive Officer

Brian Hahn - Senior Vice President and Chief Financial Officer

Bruce Johnson - Senior Vice President and Chief Commercial Officer

Edwin Rock - Chief Medical Officer

Conference Call Participants

Edward White - H.C. Wainwright

Operator

Good morning and thank you for joining the GlycoMimetics Q3 2022 Earnings Call. At this time all participants are in listen-only mode. Following management's remarks, we will hold a question-and-answer session. [Operator Instructions]

I would now like to turn the call over to Christian Dinneen-Long company counsel at GlycoMimetics. Please go ahead.

Christian Dinneen-Long

Good morning. Today we will review our business updates and financial results for the quarter ended June 30 2022. The press release we issued this morning is available on the company's website @glycomimetics.com under the Investors tab.

This call is being recorded. A dial in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available for 30 days in the Investor Relations section of the company's website.

Joining me on the call today from GlycoMimetics are Harout Semerjian, Chief Executive Officer; Brian Hahn, Chief Financial Officer; Dr. Ed Rock, Chief Medical Officer; and Bruce Johnson our Chief Commercial Officer. We will start today's call with comments from Harout, who will provide a broad overview of the business and updates on uproleselan development program, followed by Ed with additional commentary on uproleselan clinical studies, including both company and investigator sponsored trials. Brian will then provide details on the company's financial position, before we open the call for Q&A.

I would like to remind you that today's call will include forward-looking statements based on current expectations. Forward-looking statements on this call may include, but are not limited to, statements about the company's product candidate, uproleselan and our other pipeline programs, along with expectations regarding our operations, cash position, and the conduct of or data from clinical trials, as well as planned or potential development, regulatory interactions or submissions, and pre-commercialization activities and strategic collaborations.

Such statements represent management's judgment and intention as of today, and involve assumptions, risks, and uncertainties. GlycoMimetics undertakes no obligation to update or revise any forward-looking statement. For information concerning the risk factors that could affect the company, please refer to our filings with the SEC, which are available from the SEC or on our website.